Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
종목 코드 STTK
회사 이름Shattuck Labs Inc
상장일Oct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
직원 수44
유형Ordinary Share
회계 연도 종료Oct 09
주소500 W. 5Th Street
도시AUSTIN
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호78701
전화15129004690
웹사이트https://www.shattucklabs.com/
종목 코드 STTK
상장일Oct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음